2fzd
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:2fzd.gif|left|200px]] | [[Image:2fzd.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_2fzd", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | + | --> | |
| - | + | {{STRUCTURE_2fzd| PDB=2fzd | SCENE= }} | |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''Human aldose reductase complexed with tolrestat at 1.08 A resolution.''' | '''Human aldose reductase complexed with tolrestat at 1.08 A resolution.''' | ||
| Line 32: | Line 29: | ||
[[Category: Steuber, H.]] | [[Category: Steuber, H.]] | ||
[[Category: Zentgraf, M.]] | [[Category: Zentgraf, M.]] | ||
| - | [[Category: | + | [[Category: High resolution crystal structure]] |
| - | [[Category: | + | [[Category: Protein-ligand complex]] |
| - | [[Category: | + | [[Category: Tim-barrel]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 04:29:36 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 01:29, 4 May 2008
Human aldose reductase complexed with tolrestat at 1.08 A resolution.
Overview
In structure-based drug design, accurate crystal structure determination of protein-ligand complexes is of utmost importance in order to elucidate the binding characteristics of a putative lead to a given target. It is the starting point for further design hypotheses to predict novel leads with improved properties. Often, crystal structure determination is regarded as ultimate proof for ligand binding providing detailed insight into the specific binding mode of the ligand to the protein. This widely accepted practise relies on the assumption that the crystal structure of a given protein-ligand complex is unique and independent of the protocol applied to produce the crystals. We present two examples indicating that this assumption is not generally given, even though the composition of the mother liquid for crystallisation was kept unchanged: Multiple crystal structure determinations of aldose reductase complexes obtained under varying crystallisation protocols concerning soaking and crystallisation exposure times were performed resulting in a total of 17 complete data sets and ten refined crystal structures, eight in complex with zopolrestat and two complexed with tolrestat. In the first example, a flip of a peptide bond is observed, obviously depending on the crystallisation protocol with respect to soaking and co-crystallisation conditions. This peptide flip is accompanied by a rupture of an H-bond formed to the bound ligand zopolrestat. The indicated enhanced local mobility of the complex is in agreement with the results of molecular dynamics simulations. As a second example, the aldose reductase-tolrestat complex is studied. Unexpectedly, two structures could be obtained: one with one, and a second with four inhibitor molecules bound to the protein. They are located in and near the binding pocket facilitated by crystal packing effects. Accommodation of the four ligand molecules is accompanied by pronounced shifts concerning two helices interacting with the additional ligands.
About this Structure
2FZD is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions., Steuber H, Zentgraf M, Gerlach C, Sotriffer CA, Heine A, Klebe G, J Mol Biol. 2006 Oct 13;363(1):174-87. Epub 2006 Aug 9. PMID:16952371 Page seeded by OCA on Sun May 4 04:29:36 2008
